Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchAndrographisAndrographis (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Andrographis for COVID-19
7 studies from 62 scientists
1,245 patients in 2 countries
Statistically significant lower risk for recovery.
2 studies from 2 independent teams in 2 countries show statistically significant improvements.
COVID-19 Andrographis studies. Feb 2024. c19early.org
0 0.5 1 1.5+ All studies 27% Hospitalization 50% Recovery 30% Viral clearance 28% RCTs 41% Early 40% Late 10% Favorsandrographis Favorscontrol
Feb 20
Covid Analysis Andrographis for COVID-19: real-time meta analysis of 7 studies
Statistically significant lower risk is seen for recovery. 2 studies from 2 independent teams in 2 countries show statistically significant improvements. Meta analysis using the most serious outcome reported shows 27% [-8‑50%] ..
Feb 2
Prasoppokakorn et al., OBM Integrative and Complementary Medicine, doi:10.21926/obm.icm.2401013 Efficacy and Safety of Andrographolide and Favipiravir Versus Favipiravir Monotherapy in Patients with Mild COVID-19 Infection: A Multicenter Randomized Controlled Trial
37% improved recovery (p=0.005). Randomized controlled trial of 82 mild COVID-19 outpatients showing significantly greater reduction in cough and lower inflammatory markers at day 7. Symptomatic improvement was significant at day 7 when combining all symptoms reported, b..
Dec 21
2023
Yarnvitayalert et al., 2023 IEEE 5th Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability, doi:10.3390/engproc2023055081 Dynamic Model of Andrographolide Therapy for COVID-19
Pharmacokinetic and pharmacodynamic modeling of andrographolide for COVID-19. The model suggests that a dose of 60mg per day of andrographolide is optimal for reducing viral load and infection. The model incorporates the diffusion of the ..
Dec 7
2023
Wijewickrama et al., Journal of Ethnopharmacology, doi:10.1016/j.jep.2023.117535 Efficacy and safety of Link Natural Sudarshana, an Ayurvedic herbal preparation in COVID-19 patients: A phase II multicenter double-blind randomized placebo-controlled trial
RCT 171 hospitalized COVID-19 patients in Sri Lanka, showing improved viral clearance and recovery, without statistical significance, for treatment with Link Natural Sudarshana (LNS). LNS is an Ayurvedic herbal preparation containing 49 m..
Nov 23
2023
Kanokkangsadal et al., Research in Pharmaceutical Sciences, doi:10.4103/1735-5362.389947 Andrographis paniculata extract versus placebo in the treatment of COVID-19: a double-blinded randomized control trial
51% lower progression (p=0.25) and 8% improved recovery (p=0.33). RCT 165 low-risk mild COVID-19 patients in Thailand receiving either 180mg/day of Andrographis paniculata extract or placebo for 5 days. No significant difference was found between groups for disease progression, though A. paniculata show..
Nov 15
2023
Bhardwaj et al., Journal of Ayurveda and Integrative Medicine, doi:10.1016/j.jaim.2023.100778 Effectiveness of ayurvedic formulation, NAOQ19 along with standard care in the treatment of mild-moderate COVID-19 patients: A double blind, randomized, placebo-controlled, multicentric trial
13% shorter hospitalization (p=0.05) and 12% faster viral clearance (p=0.02). RCT 150 mild-moderate COVID-19 patients showing faster viral clearance and shorter hospitalization with NAOQ19, a polyherbal formulation containing 13 antiviral/antinflammatory compounds. NAOQ19 ingredients include curcumin, andrographis,..
Nov 13
2023
Siridechakorn et al., Scientific Reports, doi:10.1038/s41598-023-46249-y Inhibitory efficiency of Andrographis paniculata extract on viral multiplication and nitric oxide production
In Vitro study analyzing the antiviral and anti-inflammatory properties of extracts and fractions from Andrographis paniculata, against herpes simplex virus-1 (HSV-1) and influenza A virus H3N2 as surrogates for COVID-19. The results show..
Sep 16
2023
Mohd Abd Razak et al., Natural Product Communications, doi:10.1177/1934578X231188861 In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds
In vitro study showing that of 9 phenolic compounds tested, only curcumin inhibited SARS-CoV-2 cytopathic effects in infected monkey kidney Vero E6 cells. Curcumin showed antiviral activity against wildtype, alpha, delta, and omicron vari..
Aug 22
2023
Ratiani et al., Pharmaceuticals, doi:10.3390/ph16091196 Efficacy of Kan Jang® in Patients with Mild COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial
71% lower progression (p=0.03), 70% improved recovery (p=0.07), and 41% faster viral clearance (p=0.12). RCT 140 mild COVID-19 patients treated within 3 days of onset, showing lower progression and improved recovery with Kan Jang (andrographis + eleuthero).
Aug 12
2023
Siripongboonsitti et al., Phytomedicine, doi:10.1016/j.phymed.2023.155018 Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
86% lower need for oxygen therapy (p=0.24), 37% improved recovery (p=0.28), and 5% worse viral clearance (p=0.46). RCT 146 mild/moderate COVID-19 patients in Thailand, showing no significant difference in clinical outcomes. There were very few serious outcomes.
Jun 30
2023
Pu et al., Phytomedicine, doi:10.1016/j.phymed.2023.154753 The effects and mechanisms of the anti-COVID-19 traditional Chinese medicine, Dehydroandrographolide from Andrographis paniculata (Burm.f.) Wall, on acute lung injury by the inhibition of NLRP3-mediated pyroptosis
In Vitro and mouse study investigating the potential therapeutic effects of dehydroandrographolide (Deh), a compound from the herb Andrographis paniculata, in models of acute lung injury caused by COVID-19 infection. Deh reduced inflammat..
May 31
2023
Benjaponpitak et al., Archives of Internal Medicine Research, doi:10.26502/aimr.0146 Effect of Andrographis paniculata Treatment for Nonimmune Patients with Early-Stage COVID-19 on the Prevention of Pneumonia: A Retrospective Cohort Study
98% lower progression (p<0.0001). Retrospective 528 asymptomatic/mild patients in Thailand, showing lower progression to pneumonia with andrographis treatment.
Feb 28
2023
Shanker et al., Phytomedicine Plus, doi:10.1016/j.phyplu.2022.100398 A randomized controlled pilot study of add-on therapy of CIM-MEG19 (standardized Andrographis paniculata formulation) in mild to moderate COVID-19
91% lower progression (p=0.05), 33% faster recovery (p<0.0001), and 6% improved viral clearance (p=1). 80 mild/moderate hospitalized COVID-19 patients in India, 40 treated with CIM-MEG19 (standardized Andrographis paniculata formulation), showing faster recovery, lower progression, and favorable changes in inflammatory markers, however the..
Dec 31
2022
Prempree et al., OSIR, 15:4 SARS-CoV-2 Clearance from Andrographis paniculata, Boesenbergia rotunda, and Favipiravir among Mild COVID-19 Cases in Klong Prem Central Prison during Mid-2021: a Retrospective Study
19% improved viral clearance (p=0.61). Retrospective 120 patients in Thailand, showing improved viral clearance with andrographis compared with favipiravir.
Sep 22
2022
Dassanayake et al., International Journal of Molecular Sciences, doi:10.3390/ijms231911131 Molecular Docking and In-Silico Analysis of Natural Biomolecules against Dengue, Ebola, Zika, SARS-CoV-2 Variants of Concern and Monkeypox Virus
In Silico study showing that the phytochemical andrographolide derived from Andrographis paniculata binds strongly to the spike proteins of six SARS-CoV-2 variants, including the B.1.1.7 UK, B.1.351 South African, P.1 Japan/Brazil, B.1.42..
Aug 10
2022
Tanwettiyanont et al., Frontiers in Medicine, doi:10.3389/fmed.2022.947373 Use of Andrographis paniculata (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised patients with mild coronavirus disease 2019: A retrospective cohort study
26% higher progression (p=0.4). Retrospective 605 hospitalized patients in Thailand, showing higher progression with andrographis, without statistical significance.
Jul 13
2022
Intharuksa et al., Molecules, doi:10.3390/molecules27144479 A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery
Review of Andrographis paniculata extracts and compounds like andrographolide with antiviral, anti-inflammatory, and immunomodulatory properties that could help treat COVID-19 symptoms and progression. In silico studies suggest these comp..
May 30
2022
Numthavaj et al., NCT05178173 Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19
Estimated 3,060 patient andrographis early treatment RCT with results not reported over 1.5 years after estimated completion.
May 12
2021
Zhang et al., Phytotherapy Research, doi:10.1002/ptr.7141 Efficacy and safety of Xiyanping injection in the treatment of COVID ‐19: A multicenter, prospective, open‐label and randomized controlled trial
92% lower severe cases (p=0.03), 48% improved recovery (p=0.008), and 53% improved viral clearance (p=0.0001). RCT 130 hospitalized COVID-19 patients in China, showing lower progression and improved recovery with Xiyanping injection (9-dehydro-17-hydro-andrographolide and sodium 9-dehydro-17-hydro-andrographolide-19-yl sulfate, which are derived f..
Dec 27
2021
Bhardwaja et al., Research Square, doi:10.21203/rs.3.rs-1165680/v1 An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial
89% improved recovery (p=0.05) and 24% improved viral clearance (p=0.47). Small RCT with 39 patients treated with NOQ19 and 37 placebo patients, showing improved recovery, without statistical significance. NOQ19 has multiple ingredients including curcumin, andrographis, and antiandrogen glycyrrhiza glabra.
Jul 11
2021
Wanaratna et al., Archives of Internal Medicine Research, doi:10.26502/aimr.0125 (date from preprint) Efficacy and Safety of Andrographis Paniculata Extract in Patients with Mild COVID-19: A Randomized Controlled Trial
86% lower progression (p=0.11) and 40% improved viral clearance (p=0.11). RCT 63 mild COVID-19 patients showing lower progression and improved viral clearance with andrographis, without statistical significance.
Oct 16
2020
Rajagopal et al., Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-020-00126-x Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach
In Silico study of several phytochemical compounds from Curcuma longa (turmeric) and Andrographis paniculata for their potential activity against COVID-19 by targeting the SARS-CoV-2 main protease. Molecular docking analysis found the tur..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit